LENZ Therapeutics (LENZ) Expected to Announce Quarterly Earnings on Wednesday

LENZ Therapeutics (NASDAQ:LENZ) is expected to issue its Q1 2025 quarterly earnings data after the market closes on Wednesday, May 7th. Analysts expect LENZ Therapeutics to post earnings of ($0.56) per share for the quarter.

LENZ Therapeutics (NASDAQ:LENZ) last issued its earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04). On average, analysts expect LENZ Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

LENZ Therapeutics Stock Performance

LENZ stock traded down $2.61 during midday trading on Tuesday, hitting $26.50. 50,236 shares of the stock were exchanged, compared to its average volume of 184,340. The stock has a market cap of $729.80 million, a price-to-earnings ratio of -5.60 and a beta of 0.41. LENZ Therapeutics has a fifty-two week low of $14.42 and a fifty-two week high of $38.93. The stock’s 50-day moving average price is $24.21 and its 200-day moving average price is $27.30.

Wall Street Analyst Weigh In

LENZ has been the topic of a number of research reports. Piper Sandler began coverage on shares of LENZ Therapeutics in a research note on Monday, April 14th. They issued an “overweight” rating and a $51.00 price objective on the stock. TD Cowen initiated coverage on shares of LENZ Therapeutics in a research note on Tuesday, March 18th. They set a “buy” rating and a $60.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 target price on shares of LENZ Therapeutics in a research note on Wednesday, April 16th. Finally, Citigroup raised their price target on LENZ Therapeutics from $44.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday, March 20th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, LENZ Therapeutics currently has an average rating of “Buy” and an average target price of $46.60.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.